Risk of leukemia in children treated with human growth hormone: Review and reanalysis

被引:73
作者
Allen, DB
Rundle, AC
Graves, DA
Blethen, SL
机构
[1] UNIV WISCONSIN, SCH MED, DEPT PEDIAT, MADISON, WI USA
[2] GENENTECH INC, DEPT MED AFFAIRS, S SAN FRANCISCO, CA 94080 USA
关键词
D O I
10.1016/S0022-3476(97)70008-8
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Background: Data have suggested that any increased incidence of leukemia in growth-hormone (GH)-treated patients mas limited to those with known risk factors for leukemia. However, previous studies may have overestimated the numbers of patient-years of risk by not excluding data from ''positive-risk-factor'' patients. This risk was reanalyzed by using data on children in the National Cooperative Growth Study (NCGS), with correction for this possible confounding factor. Methods: The risk of leukemia in GH-treated patients without known risk factors was determined by using patient-years of GH therapy and patient years since first exposure to GH therapy and the values obtained were compared with values fr om the Surveillance, Epidemiology, and End Results program of the National Cancer Institute. Results: Three cases of leukemia in patients without known risk factors were found in the NCGS database; 3.42 cases would be expected in the 119,846 patient-years in the analysis using time since GH exposure. Two of these cases of leukemia occurred during CH therapy (67,773 patient-years); 2.13 cases would be expected. Conclusion: Excluding data on patients with known risk factors for leukemia provides a more accurate estimate of the risks in GH-treated patients. The incidence of leukemia in these patients is comparable to that in the general population of age-matched children.
引用
收藏
页码:S32 / S36
页数:5
相关论文
共 10 条
[1]  
ALLEN DB, 1996, J PEDIATR, V128, pS8
[2]  
Breslow N. E., 1987, STAT METHODS CANC RE, VII, P65
[3]   RISK OF LEUKEMIA AFTER TREATMENT WITH PITUITARY GROWTH-HORMONE [J].
FRADKIN, JE ;
MILLS, JL ;
SCHONBERGER, LB ;
WYSOWSKI, DK ;
THOMSON, R ;
DURAKO, SJ ;
ROBISON, LL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 270 (23) :2829-2832
[4]  
FRISCH H, 1988, LANCET, V331, P1335
[5]  
KOSARY CL, 1995, NIH PUBLICATION
[6]  
*LAWS WILK PED END, 1988, INT WORKSH GROWTH HO
[7]   LEUKEMIA IN GROWTH-HORMONE-TREATED PATIENTS - AN UPDATE, 1992 [J].
STAHNKE, N .
HORMONE RESEARCH, 1992, 38 :56-62
[8]  
WATANABE S, 1988, LANCET, V1, P1159
[9]   RISK-FACTORS FOR LEUKEMIA OCCURRENCE AMONG GROWTH-HORMONE USERS [J].
WATANABE, S ;
YAMAGUCHI, N ;
TSUNEMATSU, Y ;
KOMIYAMA, A .
JAPANESE JOURNAL OF CANCER RESEARCH, 1989, 80 (09) :822-825
[10]  
WATANABE S, 1993, J PEDIATR ENDOCRINOL, V6, P99